Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

Inclusion criteria

• ✓. Diagnosis of one of the following
• ✓. Patients ≥ 18 years of age with relapsed/refractory B- or T-cell ALL (for phase II only)
• ✓. Patients ≥ 60 years of age with previously untreated B- or T-cell ALL. Patients \<60 years of age may be enrolled if they are considered unfit for intensive chemotherapy
• ✓. Patients ≥ 60 years of age with previously treated B- or T-cell ALL who received 1-2 courses of any frontline chemotherapy. Patients \<60 years of age may be enrolled if they are considered unfit for intensive chemotherapy
• ✓. Performance status ≤ 3 (Eastern Cooperative Oncology Group \[ECOG\] Scale)
• ✓. Adequate liver and renal function as defined by the following criteria:
• ✓. For females of childbearing potential, a negative pregnancy test must be documented within 1 week of starting treatment
• ✓. Female and male patients who are fertile must agree to use an effective form of contraception (birth control methods while on study, such as birth control pills or injections, intrauterine devices \[IUDs\]), or double-barrier methods (for example, a condom in combination with spermicide) with their sexual partners for 4 months after the end of treatment

Exclusion criteria